Masitinib for the treatment of mild to moderate Alzheimer's disease

Expert Review of Neurotherapeutics

Volumn 15, Issue 6, 2015, Pages 587-596

  Folch, Jaume ^a   Petrov, Dmitry ^b   Ettcheto, Miren ^b   Pedrós, Ignacio ^a   Abad, Sonia ^b   Beas Zarate, Carlos ^c,d   Lazarowski, Alberto ^e   Marin, Miguel ^f   Olloquequi, Jordi ^g   Auladell, Carme ^b   Camins, Antoni ^b,f  

^a FACULTAT DE MEDICINA I CIÈNCIES DE LA SALUT   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY OF GUADALAJARA   (Mexico)

^d INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^e University of Buenos Aires   (Argentina)

^f UNIVERSIDAD NACIONAL DE LOJA   (Ecuador)

^g UNIVERSIDAD AUTÓNOMA DE CHILE   (Chile)

Author keywords

Alzheimer; inflammation; masitinib; neurodegeneration; tau

Indexed keywords

MASITINIB; STEM CELL FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; THIAZOLE DERIVATIVE;

ALZHEIMER DISEASE; CELL INTERACTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; GLIA CELL; HUMAN; MAST CELL; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; ANIMAL; CHEMISTRY; METABOLISM;

ALZHEIMER DISEASE; ANIMALS; HUMANS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; THIAZOLES;

EID: 84930465723     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2015.1045419     Document Type: Review

References (91)

1. Roberson ED, Mucke L. 100 years and counting: prospects for defeating Alzheimer's disease. Science 2006; 314(5800):781-4
2. Anand R, Gill KD, Mahdi AA. Therapeutics of Alzheimer's disease: Past, present and future. Neuropharmacology 2014;76(Part A):27-50
3. Tayeb HO, Yang HD, Price BH, et al. Pharmacotherapies for Alzheimer's disease: Beyond cholinesterase inhibitors. Pharmacol Ther 2012;134(1):8-25
4. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature 2004; 430(7000):631-9
5. Hardy J, Bogdanovic N, Winblad B, et al. Pathways to Alzheimer's disease. J Intern Med 2014;275(3):296-303
6. Dumas JA, Newhouse PA. The cholinergic hypothesis of cognitive aging revisited again: cholinergic functional compensation. Pharmacol Biochem Behav 2011;99(2): 254-61
7. Castellani RJ, Perry G. Pathogenesis and disease-modifying therapy in Alzheimer's disease: the flat line of progress. Arch Med Res 2012;43(8):694-8
8. Esposito Z, Belli L, Toniolo S, et al. Amyloid b, glutamate, excitotoxicity in Alzheimer's disease: are we on the right track? CNS Neurosci Ther 2013;19(8): 549-55
9. Piette F, Belmin J, Vincent H, et al. Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial. Alzheimers. Res Ther 2011; 3(2):16
10. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 1991;12(10):383-8
11. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992;256(5054):184-5
12. Armstrong RA. A critical analysis of the "amyloid cascade hypothesis". Folia Neuropathol 2014;52(3):211-25
13. Mullane K, Williams M. Alzheimer's therapeutics: Continued clinical failures question the validity of the amyloid hypothesis-But what lies beyond? Biochem Pharmacol 2014;85(3):289-305
14. Mangialasche F, Solomon A, Winblad B, et al. Alzheimer's disease: clinical trials and drug development. Lancet Neurol 2010; 9(7):702-16
15. Schneider LS, Mangialasche F, Andreasen N, et al. Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. J Intern Med 2014;275(3):251-83
16. Hefti F, Goure WF, Jerecic J, et al. The case for soluble A oligomers as a drug target in Alzheimer's disease. Trends Pharmacol Sci 2013;34(5):261-6
17. Mattson MP. Mother's legacy: mitochondrial DNA mutations and Alzheimer's disease. Trends Neurosci 1997; 20(9):373-5
18. Swerdlow RH. Mitochondria and cell bioenergetics: increasingly recognized components and a possible etiologic cause of Alzheimer's disease. Antioxid Redox Signal 2012;16(12):1434-55
19. Sims-Robinson C, Kim B, Rosko A, et al. How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol 2010; 6(10):551-9
20. Letiembre M, Liu Y, Walter S, et al. Screening of innate immune receptors in neurodegenerative diseases: a similar pattern. Neurobiol Aging 2009;30(5):759-68
21. Silver R, Curley JP. Mast cells on the mind: New insights and opportunities. Trends Neurosci 2013;36(9):513-21
22. Debruin EJ, Gold M, Lo BC, et al. Mast cells in human health and disease. Methods Mol Biol 2015;1220:93-119
23. Zappulla JP, Arock M, Mars LT, et al. Mast cells: new targets for multiple sclerosis therapy? J Neuroimmunol 2002;131(1-2): 5-20
24. Frenzel L, Hermine O. Mast cells and inflammation. Jt Bone Spine 2013;80(2): 141-5
25. Walker ME, Hatfield JK, Brown MA. New insights into the role of mast cells in autoimmunity: Evidence for a common mechanism of action? Biochim Biophys Acta Mol Basis Dis 2012;1822(1):57-65
26. Skaper SD, Giusti P, Facci L. Microglia and mast cells: two tracks on the road to neuroinflammation. FASEB J 2012;26(8): 3103-17
27. Skaper SD, Facci L, Romanello S, et al. Mast cell activation causes delayed neurodegeneration in mixed hippocampal cultures via the nitric oxide pathway. J Neurochem 1996;66(3):1157-66
28. Cheng X, Shen Y, Li R. Targeting TNF: a therapeutic strategy for Alzheimer's disease. Drug Discov Today 2014;19(11): 1822-7
29. Sabatino G, Nicoletti M, Neri G, et al. Impact of IL-9 and IL-33 in mast cells. J Biol Regul Homeost Agents 2012;26(4): 577-86
30. Milovanovic M, Volarevic V, Radosavljevic G, et al. IL-33/ST2 axis in inflammation and immunopathology. Immunol Res 2012;52(1-2):89-99
31. Hendrix S, Warnke K, Siebenhaar F, et al. The majority of brain mast cells in B10.PL mice is present in the hippocampal formation. Neurosci Lett 2006;392(3):174-7
32. Silverman AJ, Sutherland a K, Wilhelm M, et al. Mast cells migrate from blood to brain. J Neurosci 2000;20(1):401-8
33. Lambracht-Hall M, Dimitriadou V, Theoharides TC. Migration of mast cells in the developing rat brain. Dev Brain Res 1990;56(2):151-9
34. El-Agamy DS. Targeting c-kit in the therapy of mast cell disorders: Current update. Eur J Pharmacol 2012;690(1-3):1-3
35. Lennartsson J, Ronnstrand L. Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol Rev 2012; 92(4):1619-49
36. Ashman LK, Griffith R. Therapeutic targeting of c-KIT in cancer. Expert Opin Investig Drugs 2013;22(1):103-15
37. Yuzawa S, Opatowsky Y, Zhang Z, et al. Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell 2007;130(2):323-34
38. Paulhe F, Wehrle-Haller M, Jacquier MC, et al. Dimerization of Kit-ligand and efficient cell-surface presentation requires a conserved Ser-Gly-Gly-Tyr motif in its transmembrane domain. FASEB J 2009; 23(9):3037-48
39. Mol CD, Lim KB, Sridhar V, et al. Structure of a c-Kit product complex reveals the basis for kinase transactivation. J Biol Chem 2003;278(34):31461-4
40. Roskoski R. Signaling by Kit protein-tyrosine kinase - The stem cell factor receptor. Biochem Biophys Res Commun 2005;337(1):1-13
41. Roskoski R. Structure and regulation of Kit protein-tyrosine kinase-the stem cell factor receptor. Biochem Biophys Res Commun 2005;338(3):1307-15
42. Nishida T, Doi T, Naito Y. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors. Expert Opin Pharmacother 2014; 15(14):1979-89
43. Rask-Andersen M, Zhang J, Fabbro D, et al. Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci 2014;35(11):604-20
44. Azizi G, Mirshafiey A. Imatinib mesylate: an innovation in treatment of autoimmune diseases. Recent Pat Inflamm Allergy Drug Discov 2013;7(3):259-67
45. Anastassiadis T, Deacon SW, Devarajan K, et al. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol 2011; 29(11):1039-45
46. Dubreuil P, Letard S, Ciufolini M, et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS ONE 2009;4(9):e7258
47. Marech I, Patruno R, Zizzo N, et al. Masitinib (AB1010), from canine tumor model to human clinical development: Where we are? Crit Rev Oncol Hematol 2014;91(1):98-111
48. Demetri GD. Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors. Semin Oncol 2011;38:S10-19
49. Mitry E, Hammel P, Deplanque G, et al. Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol 2010;66(2):394-403
50. Kritas SK, Saggini A, Cerulli G, et al. Impact of mast cells on multiple sclerosis: inhibitory effect of natalizumab. Int J Immunopathol Pharmacol 2014;27(3):331-5
51. Kritas SK, Saggini A, Varvara G, et al. Mast cell involvement in rheumatoid arthritis. J Biol Regul Homeost Agents 2013;27(3): 655-60
52. Niederhoffer N, Levy R, Sick E, et al. Amyloid beta peptides trigger CD47-dependent mast cell secretory and phagocytic responses. Int J Immunopathol Pharmacol 2009;22(2):473-83
53. Maslinska D, Laure-Kamionowska M, Maslinski KT, et al. Distribution of tryptase-containing mast cells and metallothionein reactive astrocytes in human brains with amyloid deposits. Inflamm Res 2007;56(Suppl 1):S17-18
54. Shirazi SK, Wood JG. The protein tyrosine kinase, fyn, in Alzheimer's disease pathology. Neuroreport 1993;4(4):435-7
55. Lee G, Thangavel R, Sharma VM, et al. Phosphorylation of tau by fyn: implications for Alzheimer's disease. J Neurosci 2004; 24(9):2304-12
56. Vermersch P, Benrabah R, Schmidt N, et al. Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study. BMC Neurol 2012;12:36
57. Le Cesne A, Blay JY, Bui BN, et al. Phase II study of oral masitinib mesilate in imatinib-näve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). Eur J Cancer 2010;46(8):1344-51
58. Adenis A, Blay JY, Bui-Nguyen B, et al. Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial. Ann Oncol 2014;25(9): 1762-9
59. Sedger LM, McDermott MF. TNF and. TNF-receptors: From mediators of cell death and inflammation to therapeutic giants-past, present and future. Cytokine Growth Factor Rev 2014;25(4):453-72
60. Tebib J, Mariette X, Bourgeois P, et al. Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study. Arthritis Res Ther 2009; 11(3):R95
61. A Phase IIb/III study to evaluate efficacy and safety of masitinib in comparison to methotrexate in patients with active rheumatoid arthritis with inadequate response to methotrexate or to any disease-modifying antirheumatic drug. Available from: https://clinicaltrials.gov/ct2/show/NCT01410695
62. Efficacy of oral AB1010 in adult patients with severe persistent corticosteroid dependent asthma. Available from: https://www.clinicaltrials.gov/ct2/show/NCT00842270
63. Humbert M, De Blay F, Garcia G, et al. Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics. Allergy Eur J Allergy Clin Immunol 2009; 64(8):1194-201
64. Paul C, Sans B, Suarez F, et al. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: A phase 2a study. Am J Hematol 2010;85(12):921-5
65. Lenihan DJ, Kowey PR. Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors. Oncologist 2013;18(8):900-8
66. Soria JC, Massard C, Magne N, et al. Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers. Eur J Cancer 2009;45(13):2333-41
67. Williamson R, Scales T, Clark BR, et al. Rapid tyrosine phosphorylation of neuronal proteins including tau and focal adhesion kinase in response to amyloid-beta peptide exposure: involvement of Src family protein kinases. J Neurosci 2002;22(1):10-20
68. Yasunaga M, Yagi T, Hanzawa N, et al. Involvement of Fyn tyrosine kinase in progression of cytokinesis of B lymphocyte progenitor. J Cell Biol 1996;132(1-2):91-9
69. Sette C, Paronetto MP, Barchi M, et al. Tr-kit-induced resumption of the cell cycle in mouse eggs requires activation of a Src-like kinase. EMBO J 2002;21(20): 5386-95
70. Folch J, Junyent F, Verdaguer E, et al. Role of cell cycle re-entry in neurons: A common apoptotic mechanism of neuronal cell death. Neurotox Res 2012;22(3):195-207
71. Seward ME, Swanson E, Norambuena A, et al. Amyloid-b signals through tau to drive ectopic neuronal cell cycle re-entry in Alzheimer's disease. J Cell Sci 2013; 126(Pt 5):1278-86
72. Souter S, Lee G. Tubulin-independent tau in Alzheimer's disease and cancer: implications for disease pathogenesis and treatment. Curr Alzheimer Res 2010;7(8): 697-707
73. Chin J, Palop JJ, Puoliväli J, et al. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci 2005; 25(42):9694-703
74. Um JW, Nygaard HB, Heiss JK, et al. Alzheimer amyloid-b oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci 2012;15(9): 1227-35
75. Ittner LM, Ke YD, Delerue F, et al. Dendritic function of tau mediates amyloid-b toxicity in alzheimer's disease mouse models. Cell 2010;142(3):387-97
76. Chin J, Palop JJ, Yu GQ, et al. Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J Neurosci 2004; 24(19):4692-7
77. Penã F, Ordaz B, Balleza-Tapia H, et al. Beta-amyloid protein (25-35) disrupts hippocampal network activity: Role of Fyn-kinase. Hippocampus 2010;20(1):78-96
78. Um J, Kaufman A, Kostylev M, et al. Metabotropic glutamate receptor 5 Is a coreceptor for Alzheimer Ab oligomer bound to cellular prion protein. Neuron 2013;79(5):887-902
79. Larson M, Sherman MA, Amar F, et al. The Complex PrPc-Fyn Couples Human Oligomeric A with Pathological Tau Changes in Alzheimer's Disease. J Neurosci 2012;32(47):16857-71
80. Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's Disease. Available from: https://clinicaltrials.gov/ct2/show/NCT01864655
81. A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease. Available from: https://clinicaltrials.gov/ct2/show/NCT02167256
82. Ferreira ST, Clarke JR, Bomfim TR, et al. Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease. Alzheimer's Dement 2014; 10(Suppl 1):S76-83
83. Perry VH, Holmes C. Microglial priming in neurodegenerative disease. Nat Rev Neurol 2014;10(4):217-24
84. Liu L, Chan C. The role of inflammasome in Alzheimer's disease. Ageing Res Rev 2014;15(1):6-15
85. McGeer PL, McGeer EG. Targeting microglia for the treatment of Alzheimer's disease. Expert Opin Ther Targets 2015; 19(4):497-506
86. McGeer PL, McGeer EG. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging 2007;28(5):639-47
87. McGeer PL, McGeer EG. The amyloid cascade-inflammatory hypothesis of Alzheimer disease: Implications for therapy. Acta Neuropathol 2013;126(4):479-97
88. in t' Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001;345(21):1515-21
89. Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 2003;327(7407):128
90. Dhawan G, Combs CK. Inhibition of Src kinase activity attenuates amyloid associated microgliosis in a murine model of Alzheimer's disease. J Neuroinflammation 2012;9(1):117
91. Cochran JN, Hall AM, Roberson ED. The dendritic hypothesis for Alzheimer's disease pathophysiology. Brain Res Bull 2013;103: 18-28